Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.

Author: KingKatherine Y, MamonkinMaksim, MoFeiyan, ReadJay A, RouceRayne H

Paper Details 
Original Abstract of the Article :
Chimeric antigen receptor (CAR) T cell (CAR-T) therapy represents a revolutionary treatment for patients with relapsed/refractory hematologic malignancies. However, its use can result in significant toxicities, including cytokine release syndrome (CRS), a potentially life-threatening clinical syndro...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/36592718

データ提供:米国国立医学図書館(NLM)

CAR T Cell Therapy: Understanding the Bone Marrow Impact

Chimeric antigen receptor (CAR) T cell therapy is a revolutionary approach to treating hematologic malignancies. However, this therapy can also lead to significant side effects, including cytokine release syndrome (CRS) and prolonged bone marrow suppression. This research investigates the mechanism underlying this bone marrow suppression, exploring the potential role of proinflammatory cytokines in inducing apoptosis and depletion of hematopoietic stem and progenitor cells (HSPCs).

CRS and Bone Marrow Suppression: A Complex Interplay

The study’s findings provide compelling evidence that elevated levels of proinflammatory cytokines, particularly interferon-gamma (IFN-gamma), contribute to bone marrow suppression following CAR T cell therapy. This mechanism involves both increased apoptosis of HSPCs and enhanced proliferation of more committed progenitor cells, ultimately leading to cytopenias.

CAR T Cell Therapy: Navigating the Challenges

Understanding the complex interplay between CAR T cell therapy, CRS, and bone marrow suppression is crucial for optimizing treatment strategies and minimizing potential complications. Further research into mitigating these effects is essential for maximizing the benefits of this promising therapy.

Dr.Camel's Conclusion

CAR T cell therapy is a groundbreaking treatment for hematologic malignancies, but like a desert oasis that can be both a source of life and a hidden danger, it comes with potential side effects. This study provides valuable insights into the mechanisms behind bone marrow suppression, paving the way for improved strategies to manage this challenge and harness the full potential of CAR T cell therapy.

Date :
  1. Date Completed 2023-03-24
  2. Date Revised 2023-04-24
Further Info :

Pubmed ID

36592718

DOI: Digital Object Identifier

NIHMS1863185

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.